748724-48-3

Upstream product

• 100-52-7 benzaldehyde 
• 71-43-2 benzene 
• 80272-06-6 3-(3',4'-dichlorophenyl)-3-phenylpropanoic acid 
• 85662-98-2 3-(3',4'-dichlorophenyl)-indan-1-one 
• 7312-27-8 3,4-Dichlorocinnamic acid 
• 2025-40-3 ethyl benzylidenecyanoacetate 
• 203317-12-8 2-Cyano-3-(3,4-dichloro-phenyl)-3-phenyl-propionic acid ethyl ester 
• 113093-58-6 C₁₇H₁₆Cl₂O₂ 
• 95-50-1 1,2-dichloro-benzene 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 96850-13-4 LNK 131 hydrochloride 
• 85721-00-2 C₁₆H₁₅Cl₂N*ClH 

Relevant academic research and scientific papers

Sertraline derivative and preparation method and application thereof

The invention discloses a sertraline derivative or a medicinal salt thereof. The structural general formula of the sertraline derivative is shown in the specification. The sertraline derivative has a good inhibition effect on cryptococcus neoformans, particularly, the compound D16 disclosed by the invention has a relatively good inhibition effect on candida glabrata 9073, candida tropicalis 10186, cryptococcus neoformans, candida albicans 5314, candida albicans 904, candida tropicalis 10186, drug-resistant candida albicans 103 and cryptococcus gottii.

TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS

Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson''s disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington''s disease, and Alzheimer''s disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits the aggregation of a-synuclein.